Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Menopause & Women's Health

CoverageMenopause & Women's Health

How long should menopausal hormone therapy be continued?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·2 core studies·Applies to: perimenopausal and early postmenopausal women

Bottom line

Duration should be individualized based on symptom control, indication, and evolving risks. Many guidelines support continued use with annual reassessment rather than arbitrary stopping ages when benefits outweigh risks for that patient.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Risk-benefit balance shifts with age and time since menopause.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

HRT duration guidelines▼

Duration should be individualized based on symptom control, indication, and evolving risks. Many guidelines support continued use with annual reassessment rather than arbitrary stopping ages when benefits outweigh risks for that patient.

When to stop menopause hormone therapy▼

Duration should be individualized based on symptom control, indication, and evolving risks. Many guidelines support continued use with annual reassessment rather than arbitrary stopping ages when benefits outweigh risks for that patient.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 14 relevant studies.

Overall finding

5 studies address breast cancer, with weighted findings showing mixed findings. 5 studies address venous thromboembolism, with weighted findings showing mixed findings. 5 studies address vasomotor symptom associations, with weighted findings showing mixed findings. 4 studies address mortality, with weighted findings showing mixed findings. 7 randomized or systematic-review reports and 5 observational studies address treatment. Reassess hormone therapy annually for indication, dose, route, and evolving risks rather than stopping at an arbitrary age.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

Breast cancer

moderate · 5 studies

5 studies address breast cancer, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 32721007PMID 23543779PMID 12117397PMID 35713694PMID 36749328
Mixed

Venous thromboembolism

moderate · 5 studies

5 studies address venous thromboembolism, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 12117397PMID 26544651PMID 35713694PMID 36749328PMID 30626577
Mixed

Vasomotor symptom associations

moderate · 5 studies

5 studies address vasomotor symptom associations, with weighted findings showing mixed findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 29322164PMID 26838086PMID 38016166PMID 36749328PMID 34513605
Mixed

Mortality

moderate · 4 studies

4 studies address mortality, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 32721007PMID 23543779PMID 12117397PMID 30626577
Favors treatment

Major adverse cardiovascular events

moderate · 2 studies

2 studies address major adverse cardiovascular events, with weighted findings showing benefit. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37952131PMID 36749328
Harm signal

Fractures

moderate · 1 study

1 study addresses fractures, with weighted findings showing harm. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 12117397

Magnitude / clinical importance

Validated effect estimates in the analyzed set include HR = 1.55; or 4; odds ratio 1.58. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Most studies agree on vasomotor symptom associations (mixed findings), while breast cancer findings are mixed findings and less consistent across domains.

Supports main conclusion: 6 · Neutral / mixed: 8 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized clinical trials.
  • Consistent with WHI randomized trial findings, estrogen plus progestin use is associated with increased breast cancer incidence.
  • Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women.
  • Available evidence comparing the transdermal and oral administration routes for HRT is limited and of low quality, recommending further investigations.

Risks & harms

5 studies report safety-relevant findings. Design mix: Randomized controlled trial, Study design not clearly classified, Systematic review / meta-analysis, Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

The evidence set is heterogeneous. The most recurrent population is perimenopausal and early postmenopausal women, but several distinct groups were studied.

What remains uncertain

  • Risk-benefit balance shifts with age and time since menopause.
  • Risk-benefit balance shifts with age and time since menopause.
  • Typical subjective cognitive complaints are not established as equivalent to dementia.

Clinical takeaway

Reassess hormone therapy annually for indication, dose, route, and evolving risks rather than stopping at an arbitrary age. Many women safely continue when symptoms and benefits persist and individualized risk assessment supports ongoing use.

Mixed

Breast cancer?

Mixed findings

moderate[32721007 · 23543779 · 12117397 · 35713694 · 36749328]

Mixed

Venous thromboembolism?

Mixed findings

moderate[12117397 · 26544651 · 35713694 · 36749328 · 30626577]

Mixed

Vasomotor symptom associations?

Mixed findings

moderate[29322164 · 26838086 · 38016166 · 36749328 · 34513605]

Mixed

Mortality?

Mixed findings

moderate[32721007 · 23543779 · 12117397 · 30626577]

Favors treatment

Major adverse cardiovascular events?

Benefit

moderate[37952131 · 36749328]

Harm signal

Fractures?

Harm

moderate[12117397]

Mixed

Mood-related cognitive symptoms?

Mixed findings

moderate[29322164]

Unclear

Bone mineral density?

Unclear findings

moderate[35713694]

7 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show mixed findings.

7 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

12 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

14 analyzed studies

Strongest evidence

JAMA2020

Landmark studyPMID 32721007

Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.

The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized clinical trials. To assess the association of prior randomized use of estrogen plus progestin or prior randomized use of estrogen alon

RCT
Evidence
Relevance

Supporting literature

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.

+9 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Menopause & Women's Health.

Does hormone replacement therapy increase breast cancer risk?

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

10 linked studies

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

14 linked studies

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

14 linked studies

Is there a critical timing window for cardiovascular benefit from HRT?

The critical-window concept proposes that starting HRT closer to menopause may yield different cardiovascular effects than starting later. WHI subgroup analyses inform but do not prove this hypothesis for routine practice.

14 linked studies

Go deeper on Menopause & Women's Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Menopause & Women's HealthView pricing